ARCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross Margin % is calculated as gross profit divided by its revenue. Arcturus Therapeutics Holdings's Gross Profit for the three months ended in Dec. 2024 was $21.0 Mil. Arcturus Therapeutics Holdings's Revenue for the three months ended in Dec. 2024 was $21.0 Mil. Therefore, Arcturus Therapeutics Holdings's Gross Margin % for the quarter that ended in Dec. 2024 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.
The historical rank and industry rank for Arcturus Therapeutics Holdings's Gross Margin % or its related term are showing as below:
Arcturus Therapeutics Holdings had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Arcturus Therapeutics Holdings was 0.00% per year.
The historical data trend for Arcturus Therapeutics Holdings's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcturus Therapeutics Holdings Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Gross Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Arcturus Therapeutics Holdings Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Gross Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Arcturus Therapeutics Holdings's Gross Margin % falls into.
Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
Arcturus Therapeutics Holdings's Gross Margin for the fiscal year that ended in Dec. 2024 is calculated as
Gross Margin % (A: Dec. 2024 ) | = | Gross Profit (A: Dec. 2024 ) | / | Revenue (A: Dec. 2024 ) |
= | 138.4 | / | 138.389 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (138.389 - 0) | / | 138.389 | |
= | N/A % |
Arcturus Therapeutics Holdings's Gross Margin for the quarter that ended in Dec. 2024 is calculated as
Gross Margin % (Q: Dec. 2024 ) | = | Gross Profit (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | 21 | / | 21 | |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | (21 - 0) | / | 21 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Arcturus Therapeutics Holdings (NAS:ARCT) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Arcturus Therapeutics Holdings had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Thank you for viewing the detailed overview of Arcturus Therapeutics Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Pad Chivukula | officer: Chief Scientific Officer & COO | 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Andy Sassine | officer: Chief Financial Officer | 82 DEVONSHIRE STREET, BOSTON MA 02109 |
Keith C Kummerfeld | officer: See Remarks | 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121 |
Magda Marquet | director | ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121 |
John Markels | director | C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804 |
Joseph E Payne | director, 10 percent owner, officer: President and CEO | 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Jing L. Marantz | director | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Ultragenyx Pharmaceutical Inc. | director, 10 percent owner | 60 LEVERONI COURT, NOVATO CA 94949 |
Lance Kurata | officer: Chief Legal Officer | 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121 |
Steven George Hughes | officer: Chief Development Officer | 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
James F Barlow | director | 2525 DUPONT DR, IRVINE CA 92612 |
Edward W Holmes | director | C/O TULARIK INC, TWO CORP DRIVE SOUTH, SAN FRANCISCO CA 8608257208 |
Peter C Farrell | director | RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857 |
Karah Herdman Parschauer | director | 60 LEVERONI COURT, NOVATO CA 94949 |
From GuruFocus
By Business Wire • 10-31-2024
By GuruFocus News • 11-05-2024
By Business Wire • 03-05-2025
By Business Wire • 08-27-2024
By GuruFocus News • 11-06-2024
By GuruFocus Research • 08-07-2024
By Business Wire • 11-26-2024
By Business Wire • 11-11-2024
By Business Wire • 11-19-2024
By GuruFocus News • 03-06-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.